lixisenatide + metformin

Lixisenatide + metformin is a combination therapy used to improve glycemic control in adults with type 2 diabetes mellitus, especially in individuals inadequately controlled on metformin alone. Lixisenatide is a selective once-daily prandial **glucagon-like peptide-1 (GLP-1) receptor agonist** that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying, thereby reducing postprandial glucose excursions. Metformin is a **biguanide** that lowers glucose production in the liver and improves insulin sensitivity. The combination addresses hyperglycemia through complementary mechanisms, offering better glycemic control and potential weight loss compared to either agent alone.